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Abstract: High expression of the transmembrane protein angiotensin I converting enzyme 2 (ACE2),
more than 100-times higher as in the lung, and transmembrane serine protease 2 (TMPRSS2) in the
gastrointestinal tract leads to infection with SARS-CoV-2. According to meta-analysis data, 9.8–20%
of COVID-19 patients experience gastrointestinal symptoms, where diarrhoea is the most frequent,
and about 50% shed viruses with high titre through their faeces, where a first faecal transmission
was reported. Furthermore, gut inflammation, intestinal damage, and weakening of the gut mucosal
integrity that leads to increased permeability has been shown in different studies for COVID-19
patients. This can lead to increased inflammation and bacteraemia. Low mucosal integrity combined
with low intestinal damage is a good predictor for disease progression and submission to the intensive
care unit (ICU). Several pilot studies have shown that the gut microbiome of COVID-19 patients is
changed, microbial richness and diversity were lower, and opportunistic pathogens that can cause
bacteraemia were enriched compared to a healthy control group. In a large proportion of these
patients, dysbiosis was not resolved at discharge from the hospital and one study showed dysbiosis
is still present after 3 months post COVID-19. Consequently, there might be a link between dysbiosis
of the gut microbiome in COVID-19 patients and chronic COVID-19 syndrome (CCS). Various clinical
trials are investigating the benefit of probiotics for acute COVID-19 patients, the majority of which
have not reported results yet. However, two clinical trials have shown that a certain combination of
probiotics is beneficial and safe for acute COVID-19 patients. Mortality was 11% for the probiotic
treatment group, and 22% for the control group. Furthermore, for the probiotic group, symptoms
cleared faster, and an 8-fold decreased risk of developing a respiratory failure was calculated. In
conclusion, evidence is arising that inflammation, increased permeability, and microbiome dysbiosis
in the gut occur in COVID-19 patients and thus provide new targets for adjuvant treatments of acute
and chronic COVID-19. More research in this area is needed.
Keywords: COVID-19; SARS-CoV-2; microbiome; gut microbiome; dysbiosis; probiotics;
adjuvant treatment
1. Introduction
With nearly 200 million confirmed cases and more than 4 million deaths (WHO,
July 2021), the COVID-19 pandemic has had a huge impact on our society, economy,
and way of life. Since the discovery of COVID-19/SARS-CoV-2 in December 2019, a
staggering 1,608,720 scientific articles are now available on PubMed (28 July 2021). Huge
and impressive progress has been made with vaccination; more than 3.5 billion doses have
been administered so far (WHO, July 2021). Variants of SARS-CoV-2 are a potential threat
and other treatment options would still be advantageous.
Here, in this review, the focus is on the infection of the gut by SARS-CoV-2 and possible
treatment and prevention options. To present this in context, the interaction of SARS-
CoV-2 with the gastrointestinal tract will be briefly introduced, including gastrointestinal
symptoms, shedding of the virus in stool, probability of faecal transmission, expression
of receptor and host protease, inflammation, changes in mucosal integrity, and dysbiosis
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in the gut microbiome. In an opinion paper by the same author, the connection between
changes in the gut microbiome and chronic COVID-19 syndrome (CCS) is discussed in
detail [1].
2. Gastrointestinal Symptoms Caused by SARS-CoV-2
SARS-CoV-2 is an RNA virus that belongs to the genera Betacoronavirus [2]. Coron-
aviruses (CoVs) are known for causing respiratory and gastrointestinal diseases in animals
and humans. Young piglets are often infected by porcine epidemic diarrhoea virus (PEDV)
or porcine transmissible gastroenteritis virus (TGEV), causing acute diarrhoea, vomit-
ing, and dehydration [3]. PEDV and TEV show about 100% morbidity and 50–100%
mortality [4,5]. In cows, the bovine coronavirus (betacoronavirus) causes pneumonia and
diarrhoea in calves and adult cows [6]. In humans, 15–30% of the respiratory tract infections
each year are caused by the CoVs 229E, OC43, NL63, and HKU1 [7,8].
SARS-CoV-2 induces gastrointestinal symptoms in 9.8–20% of hospitalized patients,
according to several meta-analyses of COVID-19 patients; see Table 1. Most studies show
diarrhoea as the main syndrome, followed by nausea/vomiting and a lower frequency
of abdominal pain. Anorexia varies very widely between studies, from 1 to 79% [9]. It
is difficult to judge to what percentage of these reported symptoms is indeed a direct
consequence of the SARS-CoV-2 infection in the gut. The virus can influence the vagus
nerve and also create a cytokine storm that can cause nausea and diarrhoea [10]. Some
studies report symptoms after hospitalization and therefore the use of antibiotics, antivirals,
enteral feeding, proton pump inhibitors, and other medications can cause gastrointestinal
symptoms as well.
Two studies showed that there were no significant differences observed in critical
care patients vs non-severe patients in regards to their gastrointestinal symptoms [11–13].
The opposite observations were reported by Wang et al., showing statistical differences in
the gastrointestinal symptoms (anorexia and abdominal pain) between ICU patients and
non-ICU patients, where ICU patients had a higher percentage of these symptoms [14].
In general, the studies are often difficult to compare, since various parameters were used,
for example, the type of symptoms reported, symptoms reported at the onset of illness, or
during the hospital stay. It remains to be seen if there are regional differences or differences
concerning the SARS-CoV-2 strains.












2477 13% 7.8% 5.5% 2.7% 17 [15]
4243 17.6% 12.5% 10.2% 9.2% 60 [16]
4805 Not reported 7.4% 4.6% Not reported 29 [17]
5601 9.8% 10.4% 7.7% 6.9% 37 [18]
17,776 20% 13% 8% 4% 108 [19]
18,246 Not reported 11.5% 6.3% 2.3% 43 [20]
3. Detection of SARS-CoV-2 Infection of the Gastrointestinal Tract via Swabs or
Stool Samples
Early on in this pandemic, several routes of transmission were tested, including
the possibility of faecal transmission; see Table 2. Already in this early state, authors
were giving a cautious warning that “2019-nCoV may be transmitted through multiple
routes” [21]. Later on, Xiao et al. strongly recommended routinely testing for SARS-CoV-
2 RNA from faeces in patients with COVID-19 and transmission-based precautions for
hospitalised patients if faeces test results were positive [22]. The same authors showed
viral nucleocapsid protein expressed in gastric, duodenal, and rectum glandular epithelial
cells by immunohistologic staining.
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15 26.7% 53.3% positive in oral swabs [21]
16 25% (Day 0)37.5% (Day 5) [21]
10 100% 3–19 [23]
73 53% 1–12




74 55% Mean of 27.9 (SD 10.7) [24]
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258 36%
Virus isolated and sequenced
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monkey kidney VERO cells,
and confirmation by electron
microscopy (EM)
[26]
205 (153 tested for
faecal samples) 29% [27]
59 15.3% [16]
4243 (Meta-analysis) 48.1%





23 83.3% Mean 22 [29]
A study by Wu et al. reported that disease severity was not associated with an
extended duration of faecal sample viral RNA positivity. Faecal sample positivity lagged
behind that of respiratory tract samples. The authors recommended faecal testing to
determine the release of recovered patients. In addition, they stated that potential faecal-
oral transmission might pose an increased risk in contained living premises, such as hostels,
dormitories, trains, buses, and cruise ships [24].
Jiang et al. reported a patient (8-year-old girl) who was asymptomatic and negative
in all nasopharyngeal samples but positive at 42 days by anal swab, showing that asymp-
tomatic SARS-CoV-2 infections can still lead to a long period of transmission risk by the
oral-faecal transmission route [30]. The authors stressed that for monitoring potential
COVID-19 contact, not only nasopharyngeal but also anal swabs should be recommended.
During a close contact screening at an outbreak site, 745 children were screened using
nasopharyngeal swabs, and 1.3% were positive [31]. All of these children showed mild
or no symptoms. The viral load was monitored over time by nasopharyngeal and rectal
swabs, showing that 80% were positive for viral RNA using rectal swabs. For all of these
patients, the faecal RNA shed continued after the nasopharyngeal swabs became negative.
Similarly, Zhang et al. reported the case of three children with mild COVID-19 symptoms,
where all three cases tested SARS-CoV-2 positive in their faecal specimens within 10 days
despite negative throat swabs [32].
Chen et al. showed that the occurrence rate of gastrointestinal symptoms was not
different in patients with stool-positive vs. stool-negative samples. [25]. A study by Lin et al.
showed that from the patients with gastrointestinal symptoms, 52.4% were positive for viral
RNA compared to 39.1% of the patients without symptoms. In two patients, SARS-CoV-2
RNA was detected in oesophagus, stomach, duodenum, and rectum specimens [28].
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Byrne et al. performed a rapid scoping review on the infectious period of SARS-CoV-
2 and concluded that the maximum duration of detection ranged from approximately
20–49 days, with the longest duration associated with faecal samples [33].
4. Expression of ACE2 and TMPRSS2 in the Gastrointestinal Tract
The virus SARS-CoV-2 enters human cells via the transmembrane protein angiotensin
I converting enzyme 2 (ACE2) as a receptor. In addition, host proteases are required to
prime the spike protein, especially transmembrane serine protease 2 (TMPRSS2] [34]. ACE2
is highly expressed in the small intestine, colon, and duodenum, compared to very little
expression in the lung; see Figure 1 [35]. Immunohistochemistry on human tissue confirms
the data, showing high expression of ACE2 protein in the gastrointestinal tract but minimal
expression in the lung [22,35].
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pression levels of both ACE2 and TMPRSS2 in the gastrointestinal tract, it seems surpris-
ing that gastrointestinal symptoms are relatively mild and low in occurrence. 
5. Faecal Transmission of SARS-CoV-2 
Over 100 years ago, the ability of an infectious agent to transmit via faeces was 
demonstrated by Horrocks, showing airborne transport from one hospital building to an-
other by the sewer drains [38]. More than 60 years ago, Jessen reported bioaerosol during 
toilet flushing [39]. In many studies, it was shown that toilet flushing induces bioaerosols 
that contaminate the lid and the floor (settled particles), and also the air via droplet nuclei 
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Co-expression of the cell receptor ACE II (ACE2) and the transmembrane serine protease
2 (TMPRSS2) in esophageal upper epithelia cel s, glandular cells, and cells from the
ileum and colon was confirmed by single-cell transcriptomic analysis [37]. Given the
high expr ssion levels of both ACE2 and TMPRSS2 in the gastrointestinal tract, it seems
surprising that gastrointestinal symptoms are relatively mild and low in occurrence.
5. Faecal Transmission of SARS-CoV-2
Over 100 years ago, the ability of an infectious agent to transmit via faeces was
demonstrated by Horrocks, showing airborne transport from one hospital building to
another by the sewer drains [38]. More than 60 years ago, Jessen reported bioaerosol
during toilet flushing [39]. In many studies, it was shown that toilet flushing induces
bioaerosols that contaminate the lid and the floor (settled particles), and also the air via
droplet nuclei that remain when the water in a droplet evaporates. These droplet nuclei
float with the natural air current [40–47].
As described above, SARS-CoV-2 RNA could be detected in either anal swabs or
stool specimens in 29–80% of tested patients. Several studies showed consistently that
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SARS-CoV-2 RNA can be detected in stool for up to 49 days after the onset of symptoms.
Since SARS-CoV-2 RNA is present in stool for many patients, the following question arises:
Is there live virus present and in what concentration?
Isolation of live virus from stool samples, with the ability to infect monkey kidney
VERO cells and demonstrating typical virus formation using electron microscopy (EM),
was shown in early 2020, underlining the possibility of faecal–nasal/oral transmission [48].
Xiao et al. showed the expression of viral nucleocapsid protein in gastric, duodenal, and
rectal epithelial cells, indicating active replication of the virus [22]. In addition, the authors
wrote, “Recently, we and others have isolated infectious SARS-CoV-2 from stool (unpub-
lished data), confirming the release of the infectious virions to the gastrointestinal tract”.
Xu et al. reported, “We also isolated alive viral strains from feces, indicating potential infec-
tiousness of feces”. [49]. Wölfle et al. isolated the virus SARS-CoV-2 from samples derived
from the throat or lung but could not isolate it from stool samples [50]. Wang et al. reported
the isolation of live SARS-CoV-2 from stool samples (non-diarrhoea) from two patients [27].
Zhang et al. demonstrated that live virus can be isolated from stool samples and is able to
infect and replicate in monkey kidney VERO cells [26]. The authors concluded, “The live
virus in faeces could be an important source of contamination, which may lead to infection
and further spread in areas with poor sanitary conditions”.
In a study following 23 patients in a hospital in Beijing, 66.7% tested positive using
nasal swabs but 83.3% tested positive using faeces samples. The virus shedding was
observed for 10 days (interquartile range (IQR) 8.0–17.0) in nasal-throat mixed swabs
and 22 days (IQR 15.5–23.5) in faeces [29]. The authors also reported peak viral titres for
respiratory samples of 6–9 days (106.3 copies/mL mean 2535 copies/mL) and for faeces of
14–18 days (105.8 copies/mL mean 5623 copies/mL) after the onset of illness. Wölfe et al.
reported about 3 × 106 viral particles per mL in a single faecal sample [50,51]. Infectious
virus is present in the stool; thus, could it be a silent route of transfection through faecal–
nasal/oral transmission?
Liu et al. studied the potential aerosol transmission of SARS-CoV-2 in two Wuhan
hospitals [52]. The authors reported elevated levels of viral RNA in the patient toilet
areas and recommended proper disinfection and ventilation. They also showed that
the concentration of detectable viral RNA dropped down to undetectable levels when
rigorous sanitation procedures were implemented. Van Doremalen et al. showed that
viable virus (SARS-CoV-2) could be detected in aerosols up to 3 h post aerosolization, and
up to 2–3 days on plastic and stainless steel [53]. Ong et al. followed various patients and
their environment in an outbreak centre in Singapore, sampling the air, highly touched
areas in the isolation room, and the bathroom [54]. The authors concluded that, “Toilet
bowl and sink samples were positive, suggesting that viral shedding in stool could be a
potential route of transmission”.
Similar to the Amoy Garden SARS-CoV-1 outbreak in Hong Kong [55], new evidence
for infectious faecal aerosols transmitting SARS-CoV-2 in a high-rise apartment building
in Guangzhou (China) has been presented. Three families that live in that building were
infected with SARS-CoV-2. One family reported travel history into SARS-CoV-2 hotspots;
however, the other two families did not. Despite extensive testing in the air and surfaces
at various areas, the authors could not find any other traces except the connecting pipes
of the drainage system. The authors concluded that faecal aerosol transmission may have
caused the community outbreak of COVID-19 in this circumstance [56].
The evidence is strong that faecal transmission is possible and given the fact that there
are more infectious SARS-CoV-2 variants around, more awareness of this route should
be fostered. Especially in hospitals and care homes, personal protection in dealing with
faeces and cleaning procedures for bathrooms are important. Furthermore, shared toilets
at workplaces and public toilets in trains, buses, planes, and ships can become a site of
contamination. Frequent cleaning with the right additions can mitigate this risk very well.
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6. Gut Inflammation in COVID-19 Patients
In a small study describing 40 COVID-19 patients, where 18 reported no diarrhoea, 13
where diarrhoea had ceased, and 9 with active diarrhoea [57], the group with diarrhoea, es-
pecially the active diarrhoea, showed a strong increase in faecal calprotectin concentration,
a marker for inflammation. This increase correlated with serum interleukin-6 (IL-6) concen-
tration but not C-reactive protein (CRP) or ferritin. These results were underpinned by a
study with 26 patients by Reuken et al. [58]. Both studies indicate that inflammation in the
gut may occur in COVID-19 patients with diarrhoea and/or positive rectal swabs/faeces.
The influence of COVID-19 on microbial translocation and intestinal damage was
investigated [59]. Microbial translocation is the ability of microbes or their products to
translocate across the normally very tight epithelial layer into the extraintestinal space and
systemic circulation. It occurs when the gut mucosal integrity is weakened. Oliva et al.
used three different blood markers to measure microbial translocation and intestinal
damage (lipopolysaccharide binding protein, EndoCab IgM, and intestinal fatty acid
binding protein) [59]. The cohort was comprised of 45 COVID-19 patients, where 46.6%
were admitted to ICU. The data were compared to a healthy donor group. Blood samples
taken from day 0 and day 7 showed that COVID-19 patients had both higher microbial
translocation and intestinal damage that was maintained over the 7 days. Patients with
more severe symptoms showed higher microbial translocation but low intestinal damage
compared to patients with mild symptoms. This pattern was a good predictor of disease
progression and submission to the ICU. A different study (not yet reviewed) provides
the same conclusions. In the 16 COVID-19 patients investigated, the mean levels of
lipopolysaccharide (LPS), peptidoglycan (PGN), and fatty acid-binding protein-2 (FABP2)
were all increased by about 2 fold compared to healthy controls [60]. All three markers
indicate increased gut permeability, and the authors concluded that it may be a source of
inflammation, bacteriemia, and consequently worsening of the disease.
7. SARS-CoV-2 and the Gut Microbiome
It has been shown that SARS-CoV-2 infection alters the microbiome of the lung and
leads to reduced diversity and in some cases to community collapse [61], shows different
bacterial diversity and fewer commensals compared to non-COVID-19 pneumonia [62],
and on a functional analysis “decreased potential for lipid metabolism and glycan biosyn-
thesis and metabolism pathways, and increased potential for carbohydrate metabolism
pathways” [63]. There is crosstalk between the gut and the lung, often referred to as the
“gut-lung axis”. This crosstalk is bidirectional, and the effects of the microbiome in chronic
obstructive pulmonary disease (COPD) and inflammatory bowel disease (IBD) has been
studied [64]. For a review on the lung-gut axis in respiratory diseases, see Dumas et al. [65].
Infection with SARS-CoV-2 and consequently inflammation in the lung could also lead
to changes in the gut microbiota that can further drive the inflammation response. In
addition, SARS-CoV-2 infections in the gastrointestinal tract could lead to further changes
in the microbiome. It is speculated that the composition and diversity of the “pre-infection”
microbiome and post-infection changes, and crosstalk of the gut and lung microbiome
could influence the outcome of clinical manifestation [66,67]. In principle, “optimizing” the
gut microbiome, especially in the elderly or people with diabetes type II, could positively
affect the outcome of SARS-CoV-2 infections.
Honarmand Ebrahimi performed bioinformatic analysis and concluded that members
of the microbiome (especially Proteobacteria) of the upper respiratory tract produce ACE2
homologues as well as homologues of TMPRSS2. These could reduce the infectivity of
SARS-CoV-2 since the virus would bind to bacteria instead of lung cells. Proteobacteria are
reduced in the elderly and will therefore provide less protection [68]. Proteobacteria are
also part of the human gut microbiome, but whether the same effect occurs in this more
complex environment is unclear. In addition, infection will already occur in the upper
gastrointestinal tract where a very different microbiome exists compared to the lower part.
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Similar to the lung microbiome, diversity in the gut microbiome decreases with age and
protective effects may be reduced in the elderly.
The first pilot studies of the gut microbiome of COVID-19 patients have been per-
formed, and examples are given in Table 3. These small studies have their limitations; how-
ever, they all have shown for the majority of patients that dysbiosis caused by COVID-19
was not resolved after COVID-19 symptoms eased and patients were discharged. Treat-
ment with antibiotics can also change the gut microbiota; however, in some studies, the
described changes in the microbiome were independent of antibiotic treatment. There are
various descriptions of dysbiosis. For example, according to [69], “dysbiosis is any change
to the composition of resident commensal communities relative to the community found
in healthy individuals” and according to [70], “Dysbiosis (also called dysbacteriosis) is
characterized as a disruption to the microbiota homeostasis caused by an imbalance in the
microflora, changes in their functional composition and metabolic activities, or a shift in
their local distribution”. The changes that cause dysbiosis in the microbiome seem to be
specific to COVID-19 and can be used as predictors of disease severity. Larger and more
systematic studies are urgently needed to understand the impact of SARS-CoV-2 on the
gut microbiome, especially long-term effects.
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Table 3. Examples of pilot studies investigating the changes in the gut microbiome in COVID-19 patients.
Number of COVID-19
Patients Healthy Control Age (Median)
Microbiome






55 48 (50 for Pneumonia) Gut (faecal sample)
opportunistic pathogens






















30 30 46 34 Gut (faecal sample)





24 48 49 48











14 16 63.3 40.5 Plasma (from blood)




1* Antibiotic treatment led to further depletion of multiple symbionts beneficial to host immunity, including Faecalibacterium prausnitzii, Lachnospiraceae bacterium 5_1_63FAA, Eubacterium rectale, Ruminococ-
cus obeum, and Dorea formicigenerans. 2* for COVID-19 patients loss of Ruminococcaceae family and several genera from the Lachnospiraceae family (Fusicatenibacter, Anaerostipes, Agathobacter, unclassified
Lachnospiraceae, and Eubacterium hallii group). 3* abundance of Gram-negative bacteria.
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Gou et al. discovered blood proteomic biomarkers that can predict the severity of
COVID-19 [75]. Gut microbial features like the relative abundance of Bacteroides genus,
Streptococcus genus, Lactobacillus genus, Ruminococcaceae family, Lachnospiraceae family, and
Clostridiales order will drive these biomarkers. The faecal metabolome was investigated and
showed that 45 faecal metabolites, mainly within the categories of amino acids, fatty acids,
and bile acids, can provide a link between the identified core gut microbiota, inflammation,
and COVID-19 susceptibility.
8. Targeting the Gut Microbiome as Adjunctive Therapy for COVID-19
The gastrointestinal tract does not just have a digestive function but is also responsible
for achieving immune system homeostasis. The gut-associated lymphoid tissue harbours
about 70% of the entire immune system [76]. The gut microbiome, its metabolites, and
miRNAs influence this homeostasis and also impact mucosal integrity. Weakening of
this integrity can result in further inflammation and bacteraemia. As described above,
COVID-19 leads to dysbiosis of the gut microbiome, gut inflammation, and weakening of
mucosal integrity.
According to the Food and Agriculture Organization of the United Nations World
Health Organization, probiotics are defined as “live microorganisms which when admin-
istered in adequate amounts confer a health benefit on the host.” Probiotics have been
shown to enforce mucosal integrity [77] and be beneficial for influenza virus clearing [78].
Probiotics could therefore in theory support patients with COVID-19 to lessen inflamma-
tion, prevent/reduce the very dangerous cytokine storm, and support clearing of the virus.
Several clinical trials are underway to study the impact of probiotics on COVID-19 as an
adjunctive therapy.
A study from Italy [79] enrolled 70 COVID-19 patients with moderate symptoms
(>37.5 ◦C fever, need of non-invasive oxygen therapy, and according to imaging more
than 50% lung involvement) who were treated with hydroxychloroquine (HCQ) 200 mg
twice a day, antibiotics (ABX) (azithromycin 500 mg), and Tocilizumab (TCZ), the dosage
of which was 8 mg/kg (up to a maximum of 800 mg per dose) with an interval of 12 h
two times. A group of randomly picked 28 patients (mean age 59) received probiotics as
adjunctive therapy while the remaining 48 patients (mean age 60.5) formed the control
group. In this study, Sivomixx® (SivoBiome®, Rockville, MD, USA) was used, consisting
of Streptococcus thermophilus DSM 32345, Lactobaccilus acidophilus DSM 32241, Lactobacil-
lus helveticus DSM 32242, Lacticaseibacillus paracasei DSM 32243, Lactobaccilus plantarum
DSM 32244, Lactobacillus brevis DSM 27961, Bifidobacterium lactis DSM 32246, and Bifidobac-
terium lactis DSM 32247. Patients received three equal doses per day (sum of 2400 billion
bacteria), for 14 days. Diarrhoea was resolved for 92.9% of the patients in the probiotic
group within three days, whereas in the control group, less than 10% after three days and
only about 35% after 7 days. Other symptoms like fever, asthenia, headache, myalgia, and
dyspnoea resolved in 100% of the patients after 7 days, but only in about 50% of the control
group. The author stated, “After 7 days of treatment, the calculated model showed an
8-fold significantly decreased risk to evolve a respiratory failure” [79]. In the probiotic
group, 0% of the patients were transferred to the ICU or had a lethal outcome, compared to
4.8% and 9.5%, respectively, in the control group.
The same probiotic Sivomixx® was used by the same group to enlarge the study [80].
This time, 200 patients were enrolled, where 88 received the probiotic at the same dose
(3 times daily, a total of 2400 billion bacteria). A similar treatment was provided, including
hydroxychloroquine (200 mg twice a day for 7 days), azithromycin (500 mg once a day for
7 days), lopinavir-ritonavir (400/100 mg twice a day), or darunavir–cobicistat (800/150 mg
once a day) for 14 days. The risk to be transferred to the ICU was similar in both the
control, 21.4% (mean age 64), and probiotic treatment group, 18.1% (mean age 62). There
was a significant difference in the mortality between both groups, being 22% in the control
group vs. 11% in the probiotic treatment group, clearly demonstrating the potential of this
adjuvant treatment.
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Currently, Sivomixx® is being tested in another clinical trial in Italy in conjunction with
ozone therapy and the recommend best treatment [81]. Systemic autohemotherapy (twice
a day) will be combined with 200 billion CFU/day of Sivomixx® (six sachets twice a day).
An estimated 152 participants will be enrolled, and various outcome measures determined,
with the primary outcome being the number of patients requiring orotracheal intubation.
A clinical trial in Mexico sponsored by AB Biotics, SA, has finished (May 2021), but no
data have been published yet [82]. In this intervention study, 300 COVID-19 patients with
mild symptoms were enrolled. To a randomly selected group, a probiotic was given (Lacto-
bacillus plantarum CECT 30292, Lactobacillus plantarum CECT 7484, Lactobacillus plantarum
CECT 7485 y Pediococcus acidilactici CECT 7483) once a day for 30 days. Various primary
and secondary outcomes were determined, for example, severity progression, stay at ICU
(frequency and length), mortality, and changes in the faecal microbiome.
A Canadian clinical trial has now finished (June 2021) as well, but no data have been
published yet [83]. Nasal irrigation with Probiorinse (2.4 billion colony forming units
(CFU) of Lactococcus Lactis W136, (NPN: 80085895)) twice daily for 14 days was used as
an intervention. A total of 23 COVID-19 patients were enrolled and changes in severity
were monitored for up to 28 days. Another Canadian clinical trial monitored the duration
of symptoms, severity, and changes in the oral and faecal microbiome of an estimated
84 patients [84]. A probiotic (undefined) was given to the treatment group for 25 days.
An interventional multi-centre clinical study in Spain is evaluating the probiotic Lac-
tobacillus Coryniformis K8, using a dose of 3 × 109 CFU/day for 2 months, on health care
workers [85]. The estimated enrolment is 314 participants, and the incidence and severity
of COVID-19 will be measured. In the United States at Duke University, a study is being
performed looking at the microbiome of exposed household members from COVID-19
patients. The intervention will be made by providing a probiotic consisting of Lactobacil-
lus rhamnosus GG. In total, 182 participants are expected to enrol [86,87]. A clinical trial in
Austria aims to use Omni-Biotic® 10 AAD (Bifidobacterium bifidum W23, Bifidobacterium lac-
tis W51, Enterococcus faecium W54, Lactobacillus acidophilus W37, Lactobacillus acidophilus
W55, Lactobacillus paracasei W20, Lactobacillus plantarum W1, Lactobacillus plantarum W62,
Lactobacillus rhamnosus W71, and Lactobacillus salivarius W24) as an invention for COVID-
19-related diarrhoea [88]. It is planned that an estimated 120 patients will be enrolled.
Another way to influence the gut microbiome more radically is faecal microbiota
transplant (FMT). Two cases were reported, from an 80- and a 19-year-old man, who
received an FMT to treat a Clostridioides difficile infection (CDI) [89]. Both had severe
comorbidities. Unknowingly, both were at the onset of developing COVID-19 at the time
point of the FMT. Despite the risk factors of both patients in developing severe COVID-19
symptoms, both experienced rather mild symptoms. This gave rise to a hypothesis that
FMT can be used to reduce the risk of severe illness progression. A clinical trial was started
to investigate this hypothesis [90].
9. Is There a Link between Changes in the Gut Microbiome in COVID-19 Patients and
Chronic COVID-19 Symptoms?
Evidence is accumulating that the gut microbiome is changing for COVID-19 patients
and as described above, in a large proportion of patients, these changes (dysbiosis) seem to
last. There is compelling evidence that gut microbial dysbiosis can lead to or drive various
health problems and is associated with a lower quality of life. It might be no coincidence
that more reports are being published describing the long-term effects of COVID-19. Lopez-
Leon et al. showed in a meta-analysis that about 80% of COVID-19 patients developed at
least one symptom [91]. The main symptoms of this chronic COVID-19 syndrome (CCS) (1)
were fatigue (58%), headache (44%), attention disorder (27%), hair loss (25%), and dyspnoea
(24%); however, joint pain, sleeping problems, depression, and diarrhoea were reported
as well. Fatigue, headache, attention disorders, joint pain, headaches, sleeping problems,
depression, and diarrhoea have been linked to dysbiosis in the gut microbiome [92–100].
There seems to be an intriguing overlap between these symptoms and more research in this
area might reveal new treatment options for CCS. For a more detailed discussion, see [1].
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A not yet peer-reviewed article (MedRxiv) shows a loss of diversity in the gut microbiome
in chronic COVID-19 patients who experienced severe acute COVID-19 symptoms [101],
underpinning the importance of studying this potential connection between gut dysbiosis
and chronic COVID-19.
10. Conclusions
SARS-CoV-2 is infecting the gut in a portion of COVID-19 patients, as about 20%
develop gastrointestinal symptoms, and about 50% test positive using faecal samples
or anal swabs. ACE2 and TMPRSS2 are highly expressed in the gut and explain the
reproduction of viruses there. The first studies have shown that the lung, oral, as well as
the gut microbiome changes in COVID-19 patients and for a large proportion of patients,
the changes do not resolve after discharge from the hospital. Since the gut is also a place to
maintain immune homeostasis, changes in the gut can cause or accelerate an inflammation
response, weakening of mucosal stability, and a cytokine storm, as seen in critically ill
patients. Therefore, it was hypothesized that probiotics or other interventions to favourably
change the microbiome or address increased permeability in the gut could reduce the
immune answer and be beneficial for the COVID-19 patient. Two clinical trials have now
shown the benefits of probiotics, reducing the time to symptom clearing, reducing mortality,
and decreasing the risk of developing respiratory failure by 8-fold. Several other clinical
trials are underway and will give more insight into the benefits. There also might be a link
between changes in the gut microbiome and chronic COVID-19 syndrome (CCS). More
research is needed to investigate the potential of this adjuvant treatment.
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